We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
26
Edgewise Therapeutics
EWTX
$4.28B
$47.5M 0.71%
1,781,006
-1,093,580
-38% -$21.8M
BCAX
27
Bicara Therapeutics
BCAX
$1.82B
$45.7M 0.68%
+1,795,174
New +$45.8M
CNMD icon
28
CONMED
CNMD
$1.3B
$44.2M 0.66%
614,890
-16,374
-3% -$1.16M
LKFT
29
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$40.6M 0.61%
1,411,000
– –
COGT icon
30
Cogent Biosciences
COGT
$6.68B
$40.4M 0.6%
3,744,263
– –
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$35.7B
$39.9M 0.6%
145,000
+25,200
+21% +$6.56M
EHAB
32
DELISTED
Enhabit
EHAB
$39.5M 0.59%
4,997,746
– –
EMBC icon
33
Embecta
EMBC
$193M
$38.5M 0.58%
2,730,343
+4,208
+0.2% +$61.2K
PHVS icon
34
Pharvaris
PHVS
$2.44B
$37.6M 0.56%
2,031,700
+634,421
+45% +$11.6M
CATX icon
35
Perspective Therapeutics
CATX
$341M
$37.6M 0.56%
2,817,763
– –
GPCR icon
36
Structure Therapeutics
GPCR
$3.45B
$37.1M 0.55%
844,407
– –
DAWN
37
DELISTED
Day One Biopharmaceuticals
DAWN
$36.5M 0.54%
2,617,713
-305,424
-10% -$4.36M
TXG icon
38
10x Genomics
TXG
$5.55B
$34.1M 0.51%
1,508,943
+911,943
+153% +$18.9M
CGON icon
39
CG Oncology
CGON
$6.34B
$32.1M 0.48%
850,695
+417,155
+96% +$14.6M
DCGO icon
40
DocGo
DCGO
$64.3M
$30.1M 0.45%
9,066,138
+1,870,182
+26% +$6.36M
FHTX icon
41
Foghorn Therapeutics
FHTX
$305M
$28.2M 0.42%
3,027,886
+509,386
+20% +$3.69M
MREO
42
Mereo BioPharma
MREO
$49.5M
$27.6M 0.41%
6,710,429
– –
SVRA icon
43
Savara
SVRA
$1.13B
$27.4M 0.41%
+6,465,777
New +$28.6M
INMD icon
44
InMode
INMD
$889M
$26.8M 0.4%
1,578,708
+412,004
+35% +$6.95M
PACS icon
45
PACS Group
PACS
$7.3B
$26.5M 0.4%
663,851
– –
ZBIO
46
Zenas BioPharma
ZBIO
$1.86B
$26.4M 0.4%
+1,562,942
New +$28.1M
LNTH icon
47
Lantheus
LNTH
$7B
$26.4M 0.39%
240,218
– –
PCVX icon
48
Vaxcyte
PCVX
$8.12B
$25.7M 0.38%
+225,000
New +$20.3M
PODD icon
49
Insulet
PODD
$11.4B
$25.5M 0.38%
109,600
-2,833
-3% -$582K
BNTX icon
50
BioNTech
BNTX
$23.1B
$20.7M 0.31%
174,500
-419,500
-71% -$38.6M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.